Related references
Note: Only part of the references are listed.Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer
Adnan Ali et al.
BJU INTERNATIONAL (2019)
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes
Felix Preisser et al.
EUROPEAN UROLOGY (2019)
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review
Thomas Van den Broeck et al.
EUROPEAN UROLOGY (2019)
Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy
Nicola Fossati et al.
EUROPEAN UROLOGY (2018)
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy
Daniel E. Spratt et al.
EUROPEAN UROLOGY (2018)
Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
Nina-Sophie Schmidt-Hegemann et al.
RADIATION ONCOLOGY (2018)
Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy
Pirus Ghadjar et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2018)
Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival
Detlef Bartkowiak et al.
ACTA ONCOLOGICA (2018)
Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy
S. Garcia-Barreras et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis
Giorgio Gandaglia et al.
EUROPEAN UROLOGY (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
Stephane Gilles Guerif et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival
Ahmed Abugharib et al.
JOURNAL OF UROLOGY (2017)
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
W. U. Shipley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer
Bradley J. Stish et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
Christian Carrie et al.
LANCET ONCOLOGY (2016)
Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial
Thomas Wiegel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline
Ian M. Thompson et al.
JOURNAL OF UROLOGY (2013)
Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2-4 pN+ Prostate Cancer: Results of a Matched Analysis
Alberto Briganti et al.
EUROPEAN UROLOGY (2011)
Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database
Daniel M. Moreira et al.
JOURNAL OF UROLOGY (2009)
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
Andrew J. Stephenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy
CG Rogers et al.
CANCER (2004)